Zentalis Pharmaceuticals, Inc. ZNTL

Company Overview

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for oncology. The company operates within the biotechnology and precision medicine industries, with research and development centered on targeted cancer therapies intended to address tumor-specific vulnerabilities and mechanisms of resistance. Zentalis’ primary programs have historically focused on WEE1 inhibition and other genetically defined oncology targets, with its lead asset, azenosertib, positioned as a potentially differentiated WEE1 inhibitor for multiple solid tumor indications. The company primarily serves oncology patients through collaborations with academic research institutions, clinical investigators, and pharmaceutical development partners.

Founded in 2014 and headquartered in New York, New York, Zentalis evolved from an early-stage oncology discovery platform into a publicly traded biotechnology company listed on the Nasdaq under the ticker ZNTL. The company has emphasized biomarker-driven development strategies and combination therapy approaches intended to improve efficacy and tolerability relative to earlier-generation oncology compounds. Its positioning has been shaped by its focus on synthetic lethality, DNA damage response pathways, and targeted therapies for difficult-to-treat cancers.